Group 1 - The core point of the news is that Proprius (Shanghai) Pharmaceutical Technology Development Co., Ltd. experienced a stock price decline of 5.06%, trading at 66.26 CNY per share, with a total market capitalization of 5.235 billion CNY as of the report date [1] - Proprius was established on February 22, 2013, and went public on May 17, 2022, focusing on technology development, transfer, consulting, and services in the pharmaceutical sector, with 100% of its revenue coming from services [1] Group 2 - From the perspective of major fund holdings, the Chuangjin Hexin Fund has a significant position in Proprius, holding 121,000 shares in its Chuangjin Hexin Health Mixed A Fund, which represents 4.56% of the fund's net value, ranking it as the tenth largest holding [2] - The Chuangjin Hexin Health Mixed A Fund, established on January 26, 2022, has a current scale of 47.4529 million CNY, with a year-to-date return of 9.74% and a one-year return of 38.81%, ranking 1027 out of 8847 and 3324 out of 8094 respectively [2] - The fund manager, Pi Jinsong, has been in the position for 7 years and 80 days, managing assets totaling 900 million CNY, with the best return during his tenure being 119.78% and the worst being -49.36% [2]
普蕊斯股价跌5.06%，创金合信基金旗下1只基金重仓，持有12.1万股浮亏损失42.71万元